Company Profile

Verge Genomics, now operating as Verge Labs, develops AI systems that analyze human biological and patient data for neuroscience drug development. Its CONVERGE platform identifies potential drug targets, characterizes disease biology, identifies biomarkers, and helps drug developers select patient groups for clinical trials. The technology focuses on neurological diseases and uses multimodal genomic, proteomic, and clinical data to support drug research.